Archive – Banking & Fintech

Drug firms seek cure to profit squeeze

This content was published on Feb 3, 2011 Swiss giants Novartis and Roche reported relatively healthy balance sheets for 2010, but have warned of tough times ahead. The global recession has forced the United States, Japan and European states to demand more for less from drugs firms. Roche estimates that the European and US healthcare measures will cost the group a combined SFr1…

Roche posts rise in profit in 2010

This content was published on Feb 2, 2011 Growth in sales of Roche’s anti-cancer drugs was unable to compensate for a drop in sales of the group’s Tamiflu treatment and the surge in the Swiss franc. Full-year sales fell by three per cent to SFr47.47 billion, according to figures published on Wednesday. Commenting on the Basel-based group’s performance, CEO Severin Schwan said the…

High costs of infrastructure revealed

This content was published on Feb 1, 2011 Some SFr30 billion per annum is currently spent on maintenance alone, the Swiss National Science Foundation study revealed. Two-thirds of the maintenance bill is taken up by technical infrastructure, including transport and communications, with the remainder spent on residential buildings. Researchers warn that there is a risk of a funding shortfall in road and rail…

Italians recover assets kept over Swiss border

This content was published on Jan 31, 2011 An Italian crackdown on tax cheats last year yielded €50 billion (SFr65 billion) that was hidden from tax officials. It was a 46 per cent increase on the amount recovered the previous year. Of the total, €10.5 billion was uncovered during investigations into undeclared accounts abroad. Along with Switzerland, around a quarter of those funds…

Concern as Novartis exec approved to WHO group

This content was published on Jan 29, 2011 Paul Herrling, the Swiss head of corporate research at pharmaceutical concern Novartis, was among 21 people approved this week to join a WHO expert group evaluating funding for projects into neglected tropical diseases – those illnesses affecting the poorest populations. He is the only expert in the group who is also an executive in the…

New Tunisian ministers unveiled at WEF

This content was published on Jan 29, 2011 Yassine Brahim, minister of infrastructure and transport, and Sami Zaoui, minister of information and communication technology, joined the new governor of Tunisia’s central bank, Mustapha Kamel Nabli, to announce the country is getting back to business as normal. Brahim and Zaoui, who had both been running businesses in Europe, were appointed in the last 24…

Raging commodity prices sparks fierce debate

This content was published on Jan 29, 2011 The escalating cost of basic food products, such as wheat, has provoked social unrest in the poorer parts of the world. At the same time, the increasing price of oil threatens to put a brake on recovery from the global recession. Speaking at the World Economic Forum’s annual meeting in Davos, French President Nicolas Sarkozy…

Biofuel and gold producers named and shamed

This content was published on Jan 28, 2011 Neste Oil was awarded the public prize after more than 50,000 people took part in an online poll. According to the awards organisers, the Berne Declaration and Greenpeace, it beat out competition from petrol giant BP and cigarette maker Philip Morris. Neste is the world’s biggest buyer of palm oil, used to produce its “Green…

Currency crisis is in the eye of the beholder

This content was published on Jan 27, 2011 swissinfo.ch squeezed into the packed school assembly hall at the 41st World Economic Forum (WEF) annual meeting, but left none the wiser. Sharp elbows were needed to get a seat next to the army of television cameras and it was striking how many of the audience – of what after all was only a side…

Novartis reports good growth but cautious on 2011

This content was published on Jan 27, 2011 Net profit for the year was $9.969 billion, up 18 per cent compared with 2009. However, fourth quarter profit was down six per cent due to a decline in influenza vaccine sales. The company also warned that price cuts, United States healthcare reform and generics were likely to dampen sales growth this year. Fourth quarter…

Page 569 of 1641

First … 567 568 569 570 571 … Last

Archive – Banking & Fintech

Popular Stories

Most Discussed

Archive – Banking & Fintech

More

Drug firms seek cure to profit squeeze

More

Roche posts rise in profit in 2010

More

High costs of infrastructure revealed

More

Italians recover assets kept over Swiss border

More

Concern as Novartis exec approved to WHO group

More

New Tunisian ministers unveiled at WEF

More

Raging commodity prices sparks fierce debate

More

Biofuel and gold producers named and shamed

More

Currency crisis is in the eye of the beholder

More

Novartis reports good growth but cautious on 2011

Popular Stories

Most Discussed